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Abstract
Background: Amelogenin is an extracellular matrix protein well known for its role in the organization and
mineralization of enamel. Clinically, it is used for periodontal regeneration and, due to its finding also in
predentin and intercellular spaces of dental pulp cells, it has recently been suggested for pulp capping
procedures. The aim of this study was to analyse in vitro the effect of the recombinant human full-length
amelogenin on the growth and differentiation of human dental pulp stem cells (hDPSCs).
Methods: Human DPSCs were treated with a supplement of amelogenin at a concentration of 10 ng/ml, 100 ng/
ml and 1000 ng/ml. The groups were compared to the unstimulated control in terms of cell morphology and
proliferation, mineralization and gene expression for ALP (alkaline phosphatase), DMP1 (dentin matrix protein-1)
and DSPP (dentin sialophosphoprotein).
Results: Amelogenin affects hDPSCs differently than PDL (periodontal ligament) cells and other cell lines. The
proliferation rate at two weeks is significantly reduced in presence of the highest concentration of amelogenin
as compared to the unstimulated control. hDPSCs treated with low concentrations present a downregulation of
DMP1 and DSPP, which is significant for DSPP (p = 0.011), but not for DMP1 (p = 0.395).
Conclusions: These finding suggest that the role of full-length amelogenin is not restricted to participation in
tooth structure. It influences the differentiation of hDPSC according to various concentrations and this might
impair the clinical results of pulp capping.
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Background
In 1963 Eastoe identified a protein in the tooth struc-
ture, which presented a unique amino-acid compos-
ition, different from the collagenous enamel proteins
known to this date [1]. He coined the name Amelo-
genin for it, and since then it has been considered a
tissue-specific protein. In the next four decades, since it
was identified, it was investigated in its role as a protein
involved in the nucleation of crystallites. Now this
structural role of amelogenin in tooth development has
been well-established. Self-assembling into nanosphere
aggregates and with high affinity for hydroxyapatite and
collagen, amelogenin controls the structural organization
and mineralization of enamel, being eventually replaced
by apatite mineral [2, 3]. Until recently it was thought to
be produced only from ameloblasts, being thus specifically
present only in enamel, but in 1997 Hammerstrom
showed its presence also in the apical area of developing
roots. A few years later, several studies reported amelo-
genin mRNA and protein in mineralized tissues, in cells
such as osteoblasts, osteoclasts, chondrocytes and cemen-
toblasts [4]. In 2006 Deutsch revealed the expression of
amelogenin not just in other mineralized tissues, but also
in soft tissues (brain and eye) [5]. Since then, its involve-
ment in signaling pathways has come into the limelight.
Focusing on the pulp-dentin microenvironment, Inai
et al. localized amelogenin in the predentin and in the
intercellular spaces of odontoblasts and dental pulp cells,
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using the technique of immunolabeling [6]. Thereafter it
was suggested that amelogenin, penetrating toward the
pulp, might play a role in the interaction between amelo-
blasts and odontoblasts. Although the pathway and the
downstream action of these events remain unknown, its
clinical application has advanced rapidly. Amelogenin
has been effectively used in wound healing (Xelma®,
Molnlycke Health Care, Gothenburg, Sweden) [7], and
in regenerative periodontal treatment. It has also been
propagated for off label use in pulp capping procedures.
Moreover, in vivo studies in humans and animals have
focused on enamel matrix derivatives (EMD) as pulp
capping material [8, 9]. It is derived from the porcine
extracellular enamel matrix and is constituted for the
most part by the full-length protein, though other compo-
nents such as low-density isoforms, enamelin and trans-
forming growth factor beta (TGF-beta) are also present in
the gel of propylene glycol alginate. Histological analyses
in animals following pulp capping procedures evidence
the formation of an irregular dentinal bridge, which ap-
pears to be more an osteodentin-like structure with cells
present in the heterogeneous tissue [10].
The ability of human teeth to produce partial reparative
dentin in response to different stimuli was noted before
the conception of tissue engineering. In particular, calcium
hydroxide has been successfully exploited in pulp capping
procedures since the 1920s. This suggests that progenitor
cells, present in fully developed tooth pulp, retain the abil-
ity to form functional odontoblasts. The presence of stem
cells in dental pulp was first proposed by Fitzgerald [11]
and demonstrated a decade later, in a pioneering study by
Gronthos et al. These are mesenchymal cells which have
shown the potential to differentiate toward mesenchymal
lineages (osteoblasts, smooth muscle cells, adipocytes,
chondrocytes).
Upon these findings, our main goal was to determine
if the recombinant human full-length protein, acting as
a signaling protein, has an effect on the pulp at a genetic
level, in the view of possible implications in regenerative
treatments. This study aims to analyze the potential role
of different concentrations of the full-length amelogenin
on the stem cells present in different niches within the




The human dental pulp stem cells hDPSCs were obtained
from AllCells (Alameda, CA, USA). They had been char-
acterized by the company by means of flow cytometry,
revealing a positivity for surface markers CD73, CD90,
CD105 and CD166, and negativity for CD34, CD45 and
CD133. These cells were provided at the second pas-
sage and cultivated upon arrival until the fifth passage
in minimal essential medium, α-modification (α-MEM)
with GlutaMAX™ (Life Technologies, Carlsbad, CA, USA),
supplemented with 10 % Fetal Bovine Serum Gold (PAA,
Pasching, Austria), 100 U/mL Penicillin and 100 μg/mL
Streptomicin (Sigma Aldrich, St. Louis, MO, USA). In
order to eliminate the variability of hDPSCs culture, they
were used in the same passage for all experiments. Cells
in the fifth passage were chosen, as studies report that, at
around the fifth passage, the dentinogenic markers appear
to present peak levels of expression, suggesting a greater
differentiation potential [12].
The hDPSCs were assigned to four different groups: a
control, and three groups with a serial dilution of ame-
logenin. All the experiments were carried out in bio-
logical triplicates, while PCR analyses were carried out
in technical triplicates. The control group was cultivated
in α-MEM supplemented as mentioned above, without
other additions. The same supplemented medium was
used in the amelogenin groups, adding the amelogenin
protein at a concentration of 10 ng/mL, 100 ng/mL and
1000 ng/mL. Three samples were included in each group.
The amelogenin was provided by Abnova Biotec
GmbH (Taipei, Taiwan): it is a human recombinant pro-
tein, full-length product of the gene Amelx (1-191a.a.),
weighting approximately 48 kDa, which primary se-






The cells were seeded in T25 flasks (BD Falcon, San
Jose, CA, USA), at a density of 2*104 cells/cm2 and cul-
tured in a humidified atmosphere containing 5 % CO2
at 37 °C, with the medium changed twice a week.
Cell morphology, proliferation and viability
The specimens were examined daily under inverted light
microscopy (AXIO, Zeiss, Jena, Germany). The population
doubling (PD) time and viability were evaluated passaging
the cells weekly, re-plating them in T25 flasks at the start-
ing concentration of 2*104 cells/cm2 and counting them
with an automated cell analyzer (Cedex XS, Innovatis, Ba-
sel, Switzerland), using Trypan Blue staining (Gibco,
Thermo Fisher Scientific, Karlsruhe, Germany) in a 1:2 di-
lution, according to the manufacturer’s instructions. The
PD and cumulative PD were calculated at days 7, 14 and
21 using the following formula:
PD ¼ log2 P=P0ð Þ
P0 represents the number of cells seeded at the initial
passage, P is the number of cells at the next passage.
The doubling time (DT) was calculated as follows:
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DT ¼ CT=PD
with CT being the time in culture.
Flow cytometry analysis of surface antigens
Cells were detached with Accutase (Sigma-Aldrich;
5 min at 37 °C) and then incubated with the following
mouse anti-human mAbs for 30 min on ice: CD73-
Pacific Blue™, CD90-FITC, CD105-FITC, CD166-PE,
CD34-APC, CD45-PerCP, CD117-PE (all from BioLe-
gend) and CD133-APC (Miltenyi Biotec). After two
washing steps (PBS with 2 % FBS), the sample tubes
were acquired on a BD FACSAria III (BD Biosciences)
and at least 10.000 events were recorded. Data were an-
alyzed with BD FACSDiva and FlowJo V10 software.
Immunofluorescence analysis
hDPSC were cultured on glass slides and fixed with
methanol (Carl Roth, Karlsruhe, Germany) at –20 °C for
10 min. For DMP-1 and DSPP labelling, cells were
washed with phosphate-buffered saline (PBS) with
Tween-20 (Carl Roth, Karlsruhe, Germany), and blocked
with 10 % horse serum for 1 h at room temperature.
The cells were incubated overnight at 4 °C with the pri-
mary antibodies diluted 1:200 and 1:50 to detect respect-
ively DMP-1 and DSPP (Santa Cruz Biotechnology,
Santa Cruz, CA, USA). Secondary antibodies were
AlexaFluor 488 anti-rabbit and anti-goat IgG (Invitro-
gen, Eugene, OR, USA) used in a dilution of 1:500. For
alkaline phosphatase, cells were treated with Hyaluroni-
dase (Sigma Aldrich, Steinheim, Germany) for 30 min.
After washing with PBS with Tween the same protocol
was used as for DMP-1 and DSPP. The primary antibody
was diluted 1:20. The nuclear counterstaining was per-
formed with 4’,6-diamidino-2-phenylindole (DAPI) (Invi-
trogen, Eugene, OR, USA). Negative controls for all
antibodies were carried out on the same slide omitting
the primary antibody. The staining was evaluated under
fluorescence microscope LSM 510 using a digital cam-
era, AxioCam MRc (both Carl Zeiss, Jena, Germany).
Metabolic activity
WST-1 assays were used for determining the metabolic
activity. hDPSC were seeded in 24-well plates with
3*103 cells/well and cultured for 21 days with the above
mentioned concentrations of amelogenin. Every 7 days
WST-1 (Roche Diagnostics GmbH, Mannheim, Germany)
was added according to manufacturer’s protocols and the
medium of each well was transferred in a 96-well plate.
The cells in the 24-well plates were washed three times
with PBS and further cultured in supplemented
medium. Varioskan 3.00.7 was used for spectrophoto-
metric analyses.
Polymerase chain reaction
hDPSCs in the fourth passage were harvested at conflu-
ence, and RNA was extracted. This was considered day
0. The cells were then seeded in T75 flasks (BD Falcon,
San Jose, CA, USA) at a density of 2*104 cells/cm2 and
further cultured without passaging. After 21 days cell
samples underwent a process of lysation with Trizol®
Reagent (Invitrogen, Carlsbad, CA, USA). The total
RNA was extracted using the RNeasy Mini Kit (Qiagen,
Hilden, Germany) following the manufacturer’s protocol.
To exclude contamination, RNA samples with an optical
density A260/A280 ratio between 1.8 and 2.1 were used.
Hexamer primer-based reverse transcription was per-
formed for all the samples simultaneously using the
First-Strand cDNA Synthesis Kit (Invitrogen, Carlsbad,
CA, USA). For each sample, cDNA was synthetized
using 500 ng RNA /mL.
Gene expression of alkaline phosphatase (ALP),
dentin matrix protein-1 (DMP1) and dentin sialopho-
sphoprotein (DSPP) was detected using a semiquanti-
tative PCR method. Normalisation was performed using
glyceraldehyde-6-phosphate dehydrogenase (GAPDH)
as housekeeping gene. The master mix was prepared
using FastStart DNA Master PLUS SYBR Green I
dye.
The primers GAPDH and ALP were provided by TIB-
MOLBIOL (Berlin, Germany). The primers DMP1 and
DSPP for the amplification of cDNA were designed ac-
cording to the published sequences, and provided by
Biomol GmbH (Hamburg, Germany). The primer se-
quences and the thermocycling conditions are listed in
Table 1.
The samples of the obtained cDNA for the two latter
primers were sequenced after the gel electrophoresis
run, confirming the sequence of the genes. In order to
avoid variability, the samples from all the groups in the
study were processed concurrently for each analysed
gene. To separate the cDNA fragments obtained from
the PCR, they were loaded into agarose gel with eth-
idium bromide staining. The primers used were of max-
imum 238 bp, so a 1.5 % agarose gel in Tris-Borate
EDTA (TBE) buffer and GeneRuler Low Range DNA
Ladder 25 to 700 bp (Thermo Scientific) were used. The
PCR products were then separated by electrophoresis at
70 mV and visualized under ultraviolet light. InfinityCapt
software (Vilber Lourmat, Marne-la-Valée, France) was
used as a gel documentation and quantification system.
This represents a limitation of our study. We are aware
that our data are semiquantitative and treat them as
such.
Alizarin red staining
The capacity of the full-length amelogenin to induce the
formation of mineral nodules was evaluated using Alizarin
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Red Staining (Sigma-Aldrich-A5533). In order to detect
the alleged role as an inducer, the hDPSCs were plated in
12-well plates at a concentration of 104 cells/well and cul-
tured for 21 days with the same media as described above.
The respective media were replaced every 3–4 days. Stain-
ing protocol as described by Prockop et al. was used.
Briefly, the wells were washed three times with PBS, fixed
in 70 % Ethanol at –20 °C for 1 h. They were subsequently
washed with H2O, stained for 10 min with Alizarin Red,
washed again with PBS and kept at a temperature of 4 °C.
Statistical analyses
Statistical analyses of quantitative data were performed
using SPSS Software Program (version 22, SPSS Inc,
Chicago, IL, USA). All datasets have been tested for
normal distribution using the Kolmogoroff-Smirnov
test or Shapiro-Wilk test and for homogeneity of vari-
ances using Levene test. Comparisons between different
stimulation conditions have been performed using
Wilcoxon test or Games-Howell test. Where appropriate
(comparisons between two groups) all test procedures




Cell morphology and proliferation
The monitoring of morphological changes in response
to different amelogenin concentrations revealed no sub-
stantial differences between the control and the stimu-
lated groups. The cells presented a spindle shape and
conserved a high nucleus:cytoplasm ratio 1:2 and prom-
inent nucleoli. Attention was also given to the pattern
formation as a differentiation index of the cells, as lately
published [13]. In all the flasks the plated cells were cap-
able of forming a herringbone pattern at ×5 view, with
characteristic parallel arrays observed under a magnifica-
tion of ×10 and ×20 (Fig. 1). These characteristics were
constant in all the groups at all time points.
From the results we obtained regarding proliferation,
the full-length amelogenin does not seem to significantly
affect the proliferation rate of this dental pulp cell line
(p <0.05) (Fig. 2).
The exposure of cells to 10 ng/mL human full-length
amelogenin resulted in a slight increase of the growth
rate (10 % compared to the control, p = 0.814) during
the second week of cultivation. The exposure of cells to
100 and 1000 ng/mL human full-length amelogenin re-
sulted, on the contrary, in a slight decrease of the
growth rate (8 %; p = 0.195 and 16 %; p = 0.014 respect-
ively, compared to the control) during the same week.
Presence of higher concentrations of amelogenin has sig-
nificantly reduced the proliferation rate. Also the differ-
ence in proliferation as observed for stimulation with
10 ng/mL vs. 1000 ng/mL was shown to be significantly
different. There was no statistically significant difference
in the cumulative PD (Fig. 2b), which indicated a con-
stant trend during the three weeks. Analysis on cell via-
bility showed a significant decrease after a stimulation
with 10 ng/mL and 100 ng/mL compared to the control
and to 1000 ng/mL, particularly at day 7 (p = 0.028) and
14 (p = 0.046).
Characterization of hDPSCs by flow cytometry
Freshly cultured (day 0) hDPSCs showed high expression
of CD90, CD73, CD166 and CD105 (Fig. 3a, b, c, d).
These cells also express CD34, some CD117 and CD45
but are negative for CD133. After 21 days in culture the
hDPSCs still maintained high expression of CD90,
CD73, CD166 and CD105 but were no longer positive
for CD34 and had lower expression of CD45, while the
expression levels of CD133, CD117 remained similar to
day 0 (Fig. 3). No variability was evidenced between the
study groups.
Immunofluorescence analysis
Immunofluorescence staining showed a relatively homo-
geneous pattern of protein labeling in different cells of
the same hDPSC population. Labeling for DMP1 and
ALP revealed a fibrillary intracellular pattern relatively
homogeneous throughout the whole cytoplasm (Fig. 4a
and c), while assuming a more granular appearance for
Table 1 Primer sequences and thermocycling conditions used for target cDNA
Primer Length (bp) Sequence 5′-3′ Annealing conditions for PCR
GAPDH 238 Forward: GAG TCA ACG GAT TTG GTC GT 60 °C 30 sec; × 45cy
Reverse: TTG ATT TTG GAG GGA TCT CG
ALP 196 Forward: CCA CGT CTT CAC ATT TGG TG 65 °C 30 sec; × 40cy
Reverse: AGA CTG CGC CTG GTA GTT GT
DMP1 235 Forward: ACA GCA GCT CAG CAG AGA GT 60 °C 30 sec; × 40cy
Reverse: TAA TAG CCG TCT TGG CAG TC
DSPP 237 Forward: GTC GCT GTT GTC CAA GAA GA 60 °C 30 sec; × 40cy
Reverse: ATC CTC ATC TGC TCC ATT CC
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DSPP (Fig. 4b). Positive reactions to all antibodies tested
were observed irrespective of the group analyzed.
Metabolic activity
The WST-1 assays (Fig. 5b) showed the conversion of
tetrazolium salts in formazan products to be lower in the
presence of lower quantities of amelogenin 10 and
100 ng/mL, compared to the control. This constant trend
during the first 14 days swaps at day 21. The low viability
of the cells stimulated with 10 ng/mL amelogenin is asso-
ciated with a lower metabolism of tetrazolium.
Alizarin red staining
During 21 days, the cells formed a tightly packed mono-
layer culture but without deposition of mineral aggre-
gates, as seen in the control and in the amelogenin
groups, regardless of the concentration of supplement
used. There was no addition of any osteogenic media,
and amelogenin alone does not seem to be sufficient to
elicit mineral nodule formation (Fig. 6).
Effect of rhAmelogenin on odontogenic gene expression
At PCR analyses, hDPSCs in the control group show, after
21 day in culture, a significant upregulation of all tested
differentiation marker genes, i.e., ALP (mature osteoblast/
odontoblast marker), DMP-1 and DSPP (odontoblast
markers) (Fig. 7).
In the 3-week-prolonged culture conditions there was
a tendency for confluent growth of the hDPSCs, with a
presumable increase of the cell-cell adhesion forces, thus
explaining the observed response in DNA expression
(Figs. 7 and 8, day 0 versus control day 21).
The expression of ALP at day 21 was relatively similar
for all four groups. The full-length amelogenin had little
influence on the gene expression, even at the highest
concentration tested (1000 ng/mL), (p = 0.938) (Fig. 7,
lanes 2–4).
Both, the expressions of DMP1 and DSPP were re-
duced in the presence of the lowest concentration of
amelogenin (10 ng/mL) compared to the unstimulated
control group. However, this difference was significant
for DSPP (p = 0.011) but not for DMP1 (p = 0.395). The
quantification of the results shows a downregulation that
is inversely related to the concentration of amelogenin
(Fig. 8).
Discussion
The effect of EMD has been analyzed in different studies,
with contrasting results [14]. Therefore, it is difficult to
compare them and to define a uni-directional function of
EMDs. First of all, there is variability in the cell line used,
regarding the species (human, rat, pig, etc) and the cell
type (periodontal ligament cells (PDL), bone marrow-
mesenchymal stem cells (BM-MSC), gingival cells, odon-
toblasts, etc.). Amelogenin presents a sequence that is
highly conserved among species [15–19]; therefore, the
differences should not be due to the species studied, but
rather the cell type seems more important. Another vari-
able that has more influence is the isotype of amelogenin
used. The latest studies show that different isotypes have
Fig. 1 Representative light microscopy images of human dental pulp stem cells (hDPSCs). The cells were seeded in T25 flasks at a density of
2*104cells/cm2 and cultured in minimal essential medium, α-modification supplemented with 10 % fetal bovine serum and 1 % Penicillin/Streptomicin
and monitored at day 21 (×10) (a); hDPSCs after 21 days of cultivation with a supplement of 10 ng/mL (b), 100 ng/mL (c) and 1000 ng/mL amelogenin
(d). Scale bars 100 μm
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different functions [20–22], so we should not refer to the
role of amelogenin in general, but to the role of each spe-
cific isoform. Moreover, different concentrations are re-
ported to be used ranging from 10 ng/mL to 100 μg/mL.
EMD components have been isolated from the tooth
germs in their secretory phase, and used at a concentra-
tion of 1–100 μg/mL [23]. In any case, being composed of
a mixture of several enamel proteins and amelogenin iso-
types, the composition is likely to vary qualitatively as well
as quantitatively. In vitro studies like those of Huang [24],
Izumikawa [25], and Ye [21], which have focused on single
isotypes, have actually seen a greater effect on MSC and
DPC at an optimal concentration of 100 ng/mL. This is
also why we chose the tested concentrations, and this also
permits comparability of the results with these studies.
Our results on the influence of full-length amelogenin on
cell morphology and proliferation of hDPSCs (Figs. 1
and 2) are in line with the findings of Izumikawa [25] who
tested the full-length amelogenin on rat mesenchymal
stem cells (MSC), showing similitude of this isotype
activity in both species.
In our study, human amelogenin did not induce the for-
mation of mineralized nodules in hDPSCs (Fig. 6). Our
results support the findings of Ye [21] and Tanimoto [26]
Fig. 2 Growth curve (a) and cumulative population doubling levels (b) of human dental pulp stem cells supplemented with different
amelogenin concentrations. A10, 10 ng/mL; A100, 100 ng/mL; A1000, 1000 ng/mL amelogenin; or without amelogenin supplement (control) (means
± standard deviation). *Significant differences, p <0.05
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Fig. 3 Representative histogram overlays of CD markers as analyzed by flow cytometry: CD90 (a), CD73 (b), CD166 (c), CD105 (d), CD45 (e), CD34
(f), CD133 (g), CD117 (h). Dotted line unstained control; green day 0; orange day 21
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Fig. 4 Immunofluorescence assay for dentin matrix protein-1 (a), dentin sialophosphoprotein (b) and alkaline phosphatase (c). Representative
fluorescence microscopy photographs of human dental pulp stem cells stained with respective primary antibodies after 21 days in culture. Nuclei
were stained with 4’,6-diamidino-2-phenylindole (blue). Scale bars 20 μm
Fig. 5 Viability (a) and Tetrazolium dye reduction (b) by human human dental pulp stem cells in the presence of different amelogenin
concentrations. A10 10 ng/mL; A100 100 ng/mL; A1000 1000 ng/mL amelogenin; medium without amelogenin supplement (Control) (means ±
standard deviation). *P <0.05
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who reported no mineralizing effect of the full-length
amelogenin on human dental papilla, dental pulp cells
or PDL cells. It should be mentioned that in both stud-
ies, it was not used an osteogenic supplement. This in-
dicates that amelogenin cannot act as an inducer of
mineralization. On the other hand, studies performed
using amelogenin as a supplement of osteogenic medium,
show its capacity to enhance the osteogenic differentiation
of BM-MSC [27], PDL cells or cementoblasts [26].
Even though amelogenin does not seem to be an in-
ducer, the investigation of its role as an enhancer of the
osteogenic differentiation and mineralization process
might be of interest. Moreover, the role of low weight
amelogenins, which are other important components of
EMD, in mineralization has widely been confirmed
[28], and they might be responsible for the clinical ef-
fect of EMD.
Regarding the ‘self-differentiation’ of this stem cell line
(Figs. 7 and 8, day 0 vs. day 21), it might be due to the pro-
moting role of fetal bovine serum supplement as sug-
gested by Lindroos in 2009 [29]. In fact, STRO-1+
hDPSCs have been shown to consist of several interrelated
subpopulations which can spontaneously differentiate into
odontoblasts, osteoblasts, and chondrocytes [30]. From
our FACS results, this corresponds to a selection of a sub-
population of hDPSC CD34- or to a loss of expression of
CD34. As reviewed by Sidney et al. [31], there is increas-
ing evidence that this is a marker not specifically linked to
hematopoietic origin; it is also present on progenitor cells
of mesenchymal cell lines and its loss suggests lineage
commitment. The expression of different CD marker phe-
notypes correspond to a different protein setting. In con-
cordance with our results, Yu et al. observed increased
gene expression of ALP, DSPP and other osteoblast differ-
entiation markers, concluding that we do not have yet an
optimal medium to avoid spontaneous cell differentiation,
while permitting their amplification [32]. Another possible
theory, which does not exclude the first, involves mechan-
ical reasons: the cytoskeletal tension related to cell adhe-
sion and extracellular forces have been shown to influence
stem cell (SC) commitment [33, 34]. A remarkable finding
is the expression of odontoblast-related genes, DMP1 and
DSPP in bone, which we used afterwards as a positive con-
trol. Until now DMP1 and DSPP have been considered as
odontoblasts markers. DMP1 has already been detected in
osteocytes [35]. We confirm these findings for DMP1, and
Fig. 6 Alizarin Red staining. Human dental pulp stem cells seeded in 12-well plates at a concentration of 104 cells/well and cultured for 21 days
without amelogenin supplement (a, control) and with 10 (b) or 100 ng/mL (c) full-length amelogenin
Fig. 7 Expressions of alkaline phosphatase (ALP), dentin matrix protein-1 (DMP1), dentin sialophosphoprotein (DSPP) in human dental pulp stem
cells (hDPSCs). Total RNAs were extracted and reversely transcribed. The cDNAs were amplified by PCR using the primers shown in Table 1. The
PCR products were run on 1.5 % agarose gel and stained with ethidium bromide. Lane 1 hDPSC expression at the initial state; lane 2 after 21-day
cultivation in medium without amelogenin supplements; lane 3 after 21 days with 10 ng/mL amelogenin supplement in the medium; lane 4 after
21 days with 100 ng/mL amelogenin supplement in the medium; lane 5 after 21 days with 1000 ng/mL amelogenin supplement in the medium;
lane 6 negative control PCR run without cDNA; lane 7 positive control PCR run with bone cDNA. Each gene expression is the result of a different
gel electrophoresis
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for the first time proved that DSPP is also expressed in
bone. This means that we in fact, do not have a specific
marker for odontoblasts. There is a need for further inves-
tigations into the diversification between osteoblasts and
odontoblasts and how this impacts pulp regeneration
therapies.
From our results, low concentrations of amelogenin
determine a lower expression of odontoblast differenti-
ation genes (Figs. 7 and 8). This is suggestive of main-
tenance of an undifferentiated status of the cells, similar
to the starting cells at day 0, even preventing spontan-
eous differentiation visible in the control cultures. The
higher effectiveness of lower concentrations of the pro-
tein can be explained by its three-dimensional structure
and its capacity to assembly into nanospheres as de-
scribed by Fang in 2011 [36]. In particular, the full-
length protein has an internal structure constituted of
dodecamers, not present in other isotypes. Furthermore,
it is widely known that self-assembly is a common prop-
erty of many extracellular organic matrix macromole-
cules [37], facilitated by intermolecular interactions and
specifically assembly of amelogenins into nanosphere in-
creases at increasing concentrations.
We explained the results with the presence of the pro-
tein in a monomeric state at lower concentrations, having
thus a higher impact on cell signaling. On the contrary an
increasing assembly into nanospheres at higher concentra-
tions leads to its structural role. Our results support the
previously reported role of amelogenin as a signaling
molecule, adding the hDPSCs as another target of this
protein.
Other studies of PDL cells, report a proliferative effect
of EMD, but lower than that of epidermal growth factor
(EGF) and platelet-derived growth factor [38, 39]. An-
other study by Huang et al. [24] reports a proliferative
effect of the full-length amelogenin on BM-MSC, but in
this case the isoform used is the rh174. Even though
amelogenin represents the main component of EMD, we
think that these positive results might be due to the
presence of other growth factors that are components of
EMD. The different results reported in different studies
may be explainable with the use of different isoforms
Fig. 8 Relative expression patterns of alkaline phosphatase (ALP) (a), dentin matrix protein-1 (DMP1) (b) and dentin sialophosphoprotein (DSPP) (c)
in human dental pulp stem cells (hDPSCs). Gene expression in hDPSCs before (K0) and after (A10, A100, A1000) cultivation for 21 days with amelogenin
supplement of 10 ng/mL (A10), 100 ng/mL (A100), 1000 ng/mL (A1000). Control group of hDPSCs after 21 days cultivated in amelogenin-free medium
(K21). Means ± standard deviations; *significant difference at p <0.05. GAPDH glyceraldehyde-6-phosphate dehydrogenase
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and splicing products of amelogenin, with the use of
different animal or human sources of this protein and dif-
ferent cell types and also source of stem cells (embryonic
[28], apical papilla, periodontal ligament). A comprehen-
sive review focusing on this topic, specifically limited to in
vitro studies, has been published by Grandin in 2012 and
Bosshardt in 2008 [14, 40]. Recently a systematic review
has summarized and compared the results of EMD cap-
ping in animal and in human studies [41], evidencing con-
troversial results.
Conclusions
While the effects of amelogenin have been largely studied
with bone mesenchymal stem cells (BMSCs) and PDL
cells [42], to our knowledge, this is the first in vitro study
that analyzes the effect of full-length amelogenin on
hDPSCs. The results obtained suggest that amelogenin af-
fects hDPSCs differently than it does in PDL cells and
other cell lines. We show that the full-length amelogenin
seems to have a negative mitogenic impact on hDPSCs at
higher concentrations but shows a tendency for positive
mitogenic effects at lower concentrations.
This study permits a further understanding of the sig-
naling role of the full-length amelogenin. Considering
the present result on the inhibition of DMP1 and DSPP,
it seems plausible that amelogenin impairs the clinical
results of pulp capping; hence previous positive clinical
observations might have been random effects.
Further studies should focus on the molecular mecha-
nisms behind the effects of amelogenin, taking into con-
sideration that different isoforms have different roles,
and considering also the cell type used as a target of the
protein. For a possible application of amelogenin in pulp
regeneration, odontoblasts and other cell types present
in the pulp should also be analyzed.
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